Pierre Fabre Laboratories, a pharmaceutical and dermo-cosmetic company, has acquired Vertical Bio AG, a developer of novel cancer therapies. The acquisition adds VERT-002 to its oncology discovery pipeline. VERT-002 is a monoclonal antibody with a novel and differentiated mechanism of action, acting as a degrader of c-MET. The target is a known disease driver in patients with non-small cell lung cancer (NSCLC) with mutations or amplification of MET. Deal terms were not disclosed. The acquisit...